The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting.
BACKGROUND:There are different opinions of the clinical value of MRS of the brain. In selected materials MRS has demonstrated good results for characterisation of both neoplastic and non-neoplastic lesions. The aim of this study was to evaluate the supplemental value of MR spectroscopy (MRS) in a cl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6237369?pdf=render |
| _version_ | 1819161718205448192 |
|---|---|
| author | Jussi Hellström Romina Romanos Zapata Sylwia Libard Johan Wikström Francisco Ortiz-Nieto Irina Alafuzoff Raili Raininko |
| author_facet | Jussi Hellström Romina Romanos Zapata Sylwia Libard Johan Wikström Francisco Ortiz-Nieto Irina Alafuzoff Raili Raininko |
| author_sort | Jussi Hellström |
| collection | DOAJ |
| description | BACKGROUND:There are different opinions of the clinical value of MRS of the brain. In selected materials MRS has demonstrated good results for characterisation of both neoplastic and non-neoplastic lesions. The aim of this study was to evaluate the supplemental value of MR spectroscopy (MRS) in a clinical setting. MATERIAL AND METHODS:MRI and MRS were re-evaluated in 208 cases with a clinically indicated MRS (cases with uncertain or insufficient information on MRI) and a confirmed diagnosis. Both single voxel spectroscopy (SVS) and chemical shift imaging (CSI) were performed in 105 cases, only SVS or CSI in 54 and 49 cases, respectively. Diagnoses were grouped into categories: non-neoplastic disease, low-grade tumour, and high-grade tumour. The clinical value of MRS was considered very beneficial if it provided the correct category or location when MRI did not, beneficial if it ruled out suspected diseases or was more specific than MRI, inconsequential if it provided the same level of information, or misleading if it provided less or incorrect information. RESULTS:There were 70 non-neoplastic lesions, 43 low-grade tumours, and 95 high-grade tumours. For MRI, the category was correct in 130 cases (62%), indeterminate in 39 cases (19%), and incorrect in 39 cases (19%). Supplemented with MRS, 134 cases (64%) were correct, 23 cases (11%) indeterminate, and 51 (25%) incorrect. Additional information from MRS was beneficial or very beneficial in 31 cases (15%) and misleading in 36 cases (17%). CONCLUSION:In most cases MRS did not add to the diagnostic value of MRI. In selected cases, MRS may be a valuable supplement to MRI. |
| first_indexed | 2024-12-22T17:16:48Z |
| format | Article |
| id | doaj.art-21f9c42e862f4afbb02812acc8267042 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T17:16:48Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-21f9c42e862f4afbb02812acc82670422022-12-21T18:18:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011311e020733610.1371/journal.pone.0207336The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting.Jussi HellströmRomina Romanos ZapataSylwia LibardJohan WikströmFrancisco Ortiz-NietoIrina AlafuzoffRaili RaininkoBACKGROUND:There are different opinions of the clinical value of MRS of the brain. In selected materials MRS has demonstrated good results for characterisation of both neoplastic and non-neoplastic lesions. The aim of this study was to evaluate the supplemental value of MR spectroscopy (MRS) in a clinical setting. MATERIAL AND METHODS:MRI and MRS were re-evaluated in 208 cases with a clinically indicated MRS (cases with uncertain or insufficient information on MRI) and a confirmed diagnosis. Both single voxel spectroscopy (SVS) and chemical shift imaging (CSI) were performed in 105 cases, only SVS or CSI in 54 and 49 cases, respectively. Diagnoses were grouped into categories: non-neoplastic disease, low-grade tumour, and high-grade tumour. The clinical value of MRS was considered very beneficial if it provided the correct category or location when MRI did not, beneficial if it ruled out suspected diseases or was more specific than MRI, inconsequential if it provided the same level of information, or misleading if it provided less or incorrect information. RESULTS:There were 70 non-neoplastic lesions, 43 low-grade tumours, and 95 high-grade tumours. For MRI, the category was correct in 130 cases (62%), indeterminate in 39 cases (19%), and incorrect in 39 cases (19%). Supplemented with MRS, 134 cases (64%) were correct, 23 cases (11%) indeterminate, and 51 (25%) incorrect. Additional information from MRS was beneficial or very beneficial in 31 cases (15%) and misleading in 36 cases (17%). CONCLUSION:In most cases MRS did not add to the diagnostic value of MRI. In selected cases, MRS may be a valuable supplement to MRI.http://europepmc.org/articles/PMC6237369?pdf=render |
| spellingShingle | Jussi Hellström Romina Romanos Zapata Sylwia Libard Johan Wikström Francisco Ortiz-Nieto Irina Alafuzoff Raili Raininko The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. PLoS ONE |
| title | The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. |
| title_full | The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. |
| title_fullStr | The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. |
| title_full_unstemmed | The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. |
| title_short | The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. |
| title_sort | value of magnetic resonance spectroscopy as a supplement to mri of the brain in a clinical setting |
| url | http://europepmc.org/articles/PMC6237369?pdf=render |
| work_keys_str_mv | AT jussihellstrom thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT rominaromanoszapata thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT sylwialibard thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT johanwikstrom thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT franciscoortiznieto thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT irinaalafuzoff thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT railiraininko thevalueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT jussihellstrom valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT rominaromanoszapata valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT sylwialibard valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT johanwikstrom valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT franciscoortiznieto valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT irinaalafuzoff valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting AT railiraininko valueofmagneticresonancespectroscopyasasupplementtomriofthebraininaclinicalsetting |